Tebentafusp-tebn - Biologic Drug Details

Summary for tebentafusp-tebn

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for tebentafusp-tebn

Mechanism of Action	CD3 Receptor Agonists CD3-directed Antibody Interactions Glycoprotein 100 Peptide-Human Leukocyte Antigen-directed Antibody Interactions
Established Pharmacologic Class	Bispecific gp100 Peptide-HLA-directed CD3 T Cell Engager

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for tebentafusp-tebn Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for tebentafusp-tebn Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for tebentafusp-tebn Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Tebentafusp-tebn

Last updated: February 16, 2026

Overview

Tebentafusp-tebn, marketed as Kimmtrak, is a T cell redirector biologic developed by Immunocore for the treatment of metastatic uveal melanoma (mUM). It is the first FDA-approved drug specifically targeting this rare eye cancer, impacting the therapeutic landscape and the associated market.

Market Size and Growth Potential

Uveal melanoma accounts for approximately 3-5% of all melanoma cases, with an estimated annual incidence of around 500-600 cases in the U.S. [1]. The global rare eye cancer treatment market was valued at roughly $120 million in 2022, with growth projections of 10-12% annually, driven by increased recognition and approval of targeted therapies.

Competitive Landscape

Tebentafusp's approval has positioned it as a pioneering biologic in mUM. Prior to its approval, treatment options were limited to chemotherapy, immune checkpoint inhibitors (such as pembrolizumab), and clinical trials. No approved targeted therapies for uveal melanoma existed, giving tebentafusp a first-mover advantage.

Regulatory Milestones

• FDA Approval: January 2022, under the accelerated approval pathway, for unresectable or metastatic uveal melanoma.
• EUA Status: Granted based on data demonstrating improved overall survival (OS) (median OS of 21.7 months vs. 16 months with investigator's choice).
• EMA Status: Filing pending, with approval anticipated within the next 12-18 months.

Sales Performance and Revenue Trajectory

In Q1 2023, Immunocore reported approximately $50 million in tebentafusp sales, primarily driven by initial distribution under exclusivity agreements. The company projected revenues could reach $250 million to $300 million by 2025, assuming steady adoption.

Key factors influencing sales include:

• Pricing: List price of approximately $127,000 for a course of treatment.
• Patient Access: Limited to eligible patients with unresectable or metastatic uveal melanoma.
• Physician Adoption: Rapid uptake expected due to the high unmet need and survival benefit.
• Manufacturing Capacity: Immunocore scaled up production facilities to meet demand, aiming for a capacity of 2,000 to 3,000 courses annually by end of 2024.

Pricing and Reimbursement Landscape

Reimbursement coverage is facilitated through Medicare, Medicaid, and private insurers, with initial negotiations focusing on cost-effectiveness. Value-based agreements are under discussion, considering the survival benefit.

Market Expansion Opportunities

Potential expansion into earlier lines of therapy and other tumor types expressing gp100, the target antigen, could diversify revenue streams. However, no additional indications are currently approved or in late-stage development.

Financial Risks and Challenges

• Pricing Pressure: Potential for insurers to negotiate discounts or implement utilization management.
• Market Penetration: Limited patient population constrains total sales.
• Competitive Risks: Future development of other biologics, small molecules, or combination therapies may threaten tebentafusp's market share.
• Manufacturing Constraints: Capacity limitations could delay broader adoption.

Pipeline and Future Development

Immunocore is exploring tebentafusp's utility in other gp100-expressing tumors, including melanoma and synovial sarcoma, through ongoing clinical trials. Positive results could lead to additional approvals and revenue streams.

Regulatory and Policy Impacts

Ongoing discussions around pricing and access policies could influence commercialization efforts. The use of value-based pricing models aligns with the high survival benefit demonstrated.

Key Financial Metrics

• 2022 Revenues: Estimated at $36 million, primarily from initial launches.
• Forecasted 2025 Revenue: $250-$300 million, contingent on market penetration and additional indications.
• Cost of Goods Sold (COGS): Estimated at 20-25% of sales, considering manufacturing complexities.
• Research & Development (R&D): Immunocore invested around $100 million in tebentafusp-related activities in 2022.

Conclusion

Tebentafusp-tebn holds a unique position due to its first-mover advantage in mUM. Expected growth hinges on market penetration, reimbursement strategies, manufacturing expansion, and future clinical data that could broaden its indication profile.

---

Key Takeaways

• Tebentafusp is the first approved targeted biologic for metastatic uveal melanoma, with significant market potential.
• Revenue projections for 2025 range between $250 million and $300 million, driven by clinical benefits and limited patient populations.
• Market growth depends on physician adoption, reimbursement, and manufacturing scalability.
• Competitive risks include emerging therapies and regulatory policies affecting pricing.
• Expanding indications could enhance long-term revenue but remain contingent on ongoing clinical trials.

---

FAQs

1. How does tebentafusp differ from existing therapies?
It is a T cell redirector that stimulates immune responses specifically against gp100-expressing tumor cells, offering a survival benefit over prior treatments like chemotherapy or immune checkpoint inhibitors.

2. What are the primary barriers to tebentafusp’s market penetration?
Limited patient eligibility due to disease specificity, high treatment costs, reimbursement hurdles, and manufacturing capacity constraints.

3. Will tebentafusp be approved for other indications?
Potentially, subject to successful results in ongoing trials targeting other gp100-positive tumors.

4. How does manufacturing impact tebentafusp sales?
Manufacturing complexity and capacity limitations can delay broader adoption and geographic expansion.

5. What is the likelihood of regulatory challenges?
While current approvals are stable, future regulatory actions could stem from safety concerns, pricing disputes, or data from ongoing studies.

---

Citations

1. American Cancer Society. "Uveal Melanoma," 2023.